BYSANTI
LIVE

Serial Number

98181812

Owner

Vanda Pharmaceuticals Inc.

Attorney

Jayme M. Torelli

Filing Date

Sep 15, 2023

Add to watchlist:

No watchlists yet
View on USPTO

BYSANTI Trademark

Serial Number: 98181812

BYSANTI is a trademark filed by Vanda Pharmaceuticals Inc. on September 15, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Vanda Pharmaceuticals Inc. (104 trademarks)

Suite 300
Rockville, MD 20850

Entity Type: 03

Trademark Details

Filing Date

September 15, 2023

Registration Date

Not Registered

Published for Opposition

June 11, 2024

Goods & Services

Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of insomnia; Pharmaceutical preparations for the treatment and prevention of social anxiety; Pharmaceutical preparations for the treatment and prevention of performance anxiety; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of Parkinson's Disease psychosis; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder (DSPD); Pharmaceutical preparations for the treatment of Autism Spectrum Disorder (ASD); Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of covid-19 pneumonia; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 30, 2026 EXRA
SOU EXTENSION 3 GRANTED
Jan 29, 2026 EX3G
SOU EXTENSION 3 FILED
Jan 29, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 29, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 28, 2025 EXRA
SOU EXTENSION 2 GRANTED
Jun 27, 2025 EX2G
SOU EXTENSION 2 FILED
Jun 27, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 27, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 4, 2025 EXRA
SOU EXTENSION 1 GRANTED
Jan 3, 2025 EX1G
SOU EXTENSION 1 FILED
Jan 2, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 2, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 6, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 11, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jun 11, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 22, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 9, 2024 CNSA
ASSIGNED TO EXAMINER
May 9, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 30, 2023 NWOS
NEW APPLICATION ENTERED
Sep 15, 2023 NWAP